Joint Session ACOFP and AOASM: Exercise Induced Asthma. Bruce Dubin, DO, JD, FCLM, FACOI

Similar documents
+ Asthma and Athletics

Asthma Management for the Athlete

Exercise-Induced Bronchospasm. Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute

Exercise-Induced Bronchoconstriction EIB

3/14/2016. *Group 2 DOs *Review of core. *Group 1 MDs *Basic review with MDs * Anatomy * Screening * Pathophysiology * Theory behind

Lecture Notes. Chapter 3: Asthma

Financial Disclosure. Exercise Induced Bronchospasm BHR. Exercise Induced Asthma

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D.

Abnormal Spirometry Medical Risk in Aviation Conference Royal Aeronautical Society, Dec 2017

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

Systems Pharmacology Respiratory Pharmacology. Lecture series : General outline

Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.

Diagnosis, Treatment and Management of Asthma

Asthma in the Athlete

Impact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma

I have no perceived conflicts of interest or commercial relationships to disclose.

CME/CE POSTTEST CME/CE QUESTIONS

JANUARY Guide to the WADA Prohibited List and Therapeutic Use Exemptions

Medicine Dr. Kawa Lecture 1 Asthma Obstructive & Restrictive Pulmonary Diseases Obstructive Pulmonary Disease Indicate obstruction to flow of air

NON-SPECIFIC BRONCHIAL HYPERESPONSIVENESS. J. Sastre. Allergy Service

Ass. Prof. Pulmonary and Crit.Care Medical School,University of Athens

Biologic Agents in the treatment of Severe Asthma

Speaker Disclosure. Identification and Diagnosis of Asthma. Definition of Asthma. Objectives 11/9/2017

Function of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)

GETTING STARTED WITH MANNITOL CHALLENGE TESTING. Rick Ballard, RRT, RPFT Applications/Education Specialist MGC Diagnostics

Out of Proportion Portions. Tiffany Jessee, DO. ACOFP 55th Annual Convention & Scientific Seminars

Bronchial asthma. E. Cserháti 1 st Department of Paediatrics. Lecture for english speaking students 5 February 2013

Exercise-Induced Bronchoconstriction (EIB) and Asthma (EIA) in the General Population and Asthmatic Subjects

ASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides

Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network

Asthma COPD Overlap (ACO)

Sergio Bonini. Professor of Internal Medicine, Second University of Naples INMM-CNR, Rome, Italy.

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.

Some Facts About Asthma

Asthma and Vocal Cord Dysfunction

Asthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.

Allergic Conditions in Sports. Seth Smith, MD, CAQ-SM, PharmD TPC Course February 7, 2016

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy

COPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer

Asthma Management. Photo from

Presented by the California Academy of Family Physicians 2013/California Academy of Family Physicians

Chronic inflammation of the airways Hyperactive bronchi Shortness of breath Tightness in chest Coughing Wheezing

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016

Respiratory Pharmacology

Asthma 101. Introduction

7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)

Bronchial Provocation Results: What Does It Mean?

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)

Asthma Pathophysiology and Treatment

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

Asthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness

TUEC Guidelines Medical Information to Support the Decisions of TUE Committees Asthma ASTHMA

LUNG FUNCTION TESTING: SPIROMETRY AND MORE

Connecting Health & Housing: Asthma and the Home. Presented by: The California-Nevada Public Health Training Center

Outpatient Guideline for the Diagnosis and Management of Asthma

Bronchial asthma. MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL

Pediatric and Adult. Disclosure. Asthma. Learning Objectives. EPR-3: What s Changed? Asthma: Pediatric and Adult

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

Pulmonary Pearls. Medical Pearls. Case 1: Case 1 (cont.): Case 1: What is the Most Likely Diagnosis? Case 1 (cont.):

Medical Emergencies at Moderate and High Altitude

Asthma. Guide to Good Health. Healthy Living Guide

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL

MANAGING ASTHMA. Nancy Davis, RRT, AE-C

Mechanisms of action of bronchial provocation testing

**This form MUST accompany a TUE Application for a Beta-2 Agonist if submitted to USADA**

Meeting the Challenges of Asthma

The role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE

Asthma. chapter 7. Overview

COPD. Breathing Made Easier

SCREENING AND PREVENTION

Beta 2 adrenoceptor agonists and the Olympic Games in Athens

Your Guide to MANAGING ASTHMA

Asthma 2015: Establishing and Maintaining Control

TUE PHYSICIAN GUIDELINES Medical Information to Support the Decisions of TUE Committees Asthma ASTHMA

Objectives. Pulmonary Assessment 12/13/2017

MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER

Asthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015

RESPIRATORY CARE IN GENERAL PRACTICE

COPD. Helen Suen & Lexi Smith

Anyone who smokes and/or has shortness of breath and sputum production could have COPD

RESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED

REQUISITION FOR DIAGNOSTIC SERVICES

COPD: A Renewed Focus. Disclosures

(Asthma) Diagnosis, monitoring and chronic asthma management

Improving the Management of Asthma to Improve Patient Adherence and Outcomes

Efficacy of a Heat Exchanger Mask in Cold Exercise-Induced Asthma* David A. Beuther, MD; and Richard J. Martin, MD, FCCP

Asthma in Children with Sickle Cell Disease

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

Systems Pharmacology Respiratory Pharmacology. Lecture series : General outline

Learning Objective. Asthma. Discuss the pathophysiology, clinical presentation, diagnosis, and treatment of Asthma 2/22/2017

Asthma for Primary Care: Assessment, Control, and Long-Term Management

HealthPartners Care Coordination Clinical Care Planning and Resource Guide ASTHMA

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS

Asthma in the college health setting: diagnosis, treatment, pitfalls

Predicting Steroid Responsiveness using Exhaled Nitric Oxide

Provider Respiratory Inservice

Copyright, ICKE, Inc. All rights reserved. The Knowledge, Attitude, and Self-Efficacy. Asthma Questionnaire

Transcription:

Joint Session ACOFP and AOASM: Exercise Induced Asthma Bruce Dubin, DO, JD, FCLM, FACOI

ACOFP FULL DISCLOSURE FOR CME ACTIVITIES Please check where applicable and sign below. Provide additional pages as necessary. Nime of CUe Activity: 2015 AOA/ACOFP Osteopathic Medical Conference & Exposition (OMED) Dates and Location of CME Activity: October 17 - October 21. 2015 Oranqe Countv Convention Center Orlando. Florida Topic: Joint Session ACOFP/AOASM: Exercise lnduced Asthma. Sundav. October 18. 2015 8:00-8:30am Name of Speaker/Moderator: Bruce Dubin. DO. JD. FGLM, FACOI B. I have, or an immediate family member has, a financial relationship or interest with a proprietary entity producing health care goods or services. Please check the relationship(s) that applies. Research Grants Speakers' Bureaus* Ownership Consultant for Fee _ StocUBond Holdings (excluding mutual funds) Employment Partnership Others, please list: Please indicate the name(s) of the organization(s) with which you have a financial relationship or interest, and the specific clinical area(s) that correspond to the relationship(s). lf more than four se list on Organization With Which Relationship Exists Clinical Area lnvolved "lf you checked "Speakers' Bureaus" in item B, please continue:. Did you participate in company-provided speaker training related to your proposed topic?. Did you travel to participate in this training?. Did the company provide you with slides of the presentation in which you were trained as a speaker?. Did the company pay the travel/lodging/other expenses?. Did you receive an honorarium or consulting fee for pa(icipating in this training? Have you received any other type of compensation from the company? Please specify: When serving as faculty for ACOFP, will you use slides provided by a proprietary entity for your presentation and/or lecture handout materials? Will your topic involve information or data obtained from commercial speaker training? Yes: Yes: Yes: Yes: Yes: A. The content of my material(s)/presentation(s) in this CME activity will not include discussion of unapproved or investigational uses of products or devices. B. The content of my material(s)/presentation in this CME activity will include discussion of unapproved or investigational uses of products or devices as indicated below: I have read the ACOFP policy on full disclosure. lf I have indicated a financia! relationship or interest, I understand that this information will be reviewed to determine whether a conflict of interest may exist, and I may be asked to provide additional information. I understand that failure or refusal to disclose, false disclosure, or inability to resolve conflicts will require the ACOFP to identify a Signature: Bruce Dubin, DO, JD, FCLM, FACOI Please fax this form to ACOFP at 866-328-1835, or e-mai! to ioank@acofp.org as soon as possible. Deadline: Wednesday, September 23, 20't5

Pre - Participation Evaluation Exercise Induced Asthma Bruce Dubin, DO Kansas City University College of Osteopathic Medicine What is Asthma Reversible Airways Dx (Twitchy Lungs) Basic functional component present in all asthmatics Airway secretion Inflammation Bronchoconstriction. 1

Asthma 1. Variable Airway Obstruction Improvement of FEV1 >12% post - bronchodilator, ideally 15% - 20% 2. >20% over time or after corticosteroid treatment. 3. Improvement in PEF 20% post - bronchodilator or over time 4. Airway Hyper responsiveness Positive bronchial provocation test (e.g., with methacholine) Common Asthma Triggers 1. Allergic 2. Dust Mites 3. Strong Smells or Odors 4. Smoke 5. Infections 6. Emotions 7. Irritants 8. Weather 9. Certain types of physical exercise 2

Exercise-Induced Asthma Definition Symptoms 1. Bronchoconstriction related to mediator release. 2. Triggered by aerobic exercise 3. Lasts several minutes Chest tightness Cough Shortness of Breath Wheezing Underperformance Fatigue Contributing Factors for EIA 1. Cool temperatures 2. Low humidity 3. Poor air quality 4. High pollen counts 5. Coincident respiratory infection 6. Poor physical conditioning 3

Proposed Physiology of EIA 1. Alterations in the temperature of the airways 2. Alterations of the osmolarity in the epithelial lining fluid 3. Release of mediators 4. Development of bronchoconstriction. Phases of EIA Immediate Phase Transient airflow obstruction 5 15 minutes after beginning or cessation of physical exertion. 4

Phases of EIA Refractory Phase 1. 40 50%. Diminished bronchoconstriction due to exercise. 2. Begins with initial aerobic exercise and lasts up to 3 hours. 3. Unpredictable & Intermittent 4. Depletion of mast cell mediators, release of endogenous catecholamine's and protective prostaglandins Late-Phase 1. 3 9 hours after initial exercise. 2. Increase in symptoms with cough, wheezing, and SOB. Spirometry Simplified Obstructive Restrictive Combined FVC or * FEV1 * FEV1/FVC or FEF 25-75% * TLC** or 5

The Allergic History 1. Look for trigger factors 2. Elicit factors that improve breathing 3. Total history including work, hobbies, travel, environmental 4. What types of exercise 5. Family history 1. Broncho - provocation testing 2. Treadmill / Bicycle exercise with pre and post PFT s 3. Informal exercise testing 4. Eucapnic voluntary hyperventilation (EVH) Testing 6

Broncho - Provocation Testing Methacholine Histamine Specific Allergens Informal Testing Duplicating the exercise and measuring pre and post spirometry. 7

Treadmill / Bicycle Exercise In Lab, so different environment. Pre and Post spirometry Eucapnic Voluntary Hyperventilation 1. EVH - potent challenge for provoking tightness in recognized asthmatics. 2. Symptoms are the same (cough, wheeze). 3. Ventilation rates similar to exercise. 4. Similar mediators in response to EVH 8

Eucapnic Voluntary Hyperventilation 1. Standardized by U.S. Army. 2. Hyperventilate at room air. 3. 5% Carbon Dioxide, 21% Oxygen, 74% Nitrogen. 4. 30 X FEV1 or 85% of MVV 5. Duration is six minutes. 6. FEV1 measured X3 before challenge. 7. FEV1 measured X 2 immediately after challenge, and five, 10, 15, and 20 minutes after. 8. A reduction in FEV1 of 10% or more of the value before the test is considered positive. Eucapnic Voluntary Hyperventilation 9

Nonpharmacological Treatment 1. Select the right sport in the right place at the right time. 2. Warm-up so competition coincides with refractory phase. Pharmacologic Therapy 1. Beta2 Agonists 2. Mast Cell Stabilizers 3. Steroids 4. Theophylline 5. Leukotriene Receptor Antagonist 6. 5-Lipoxygenase Inhibitor 10